Insights

Focus on Rare Diseases Agios Pharmaceuticals specializes in developing treatments for rare blood disorders and other rare diseases, presenting opportunities to connect with specialized healthcare providers and rare disease clinics seeking innovative therapies.

Strategic Partnerships Recent collaborations with companies like Oscotec and Avanzanite highlight their openness to licensing and distribution deals, indicating potential for expanding distribution channels and forming new licensing agreements.

Pipeline Expansion Agios is actively advancing multiple drug candidates, including cevidoplenib and mitapivat, with plans for accelerated approval pathways, creating opportunities to offer complementary services, diagnostics, or patient management solutions in these therapeutic areas.

Regulatory Engagement Close collaboration with agencies like the FDA to finalize product labeling and REMS strategies suggests readiness for market entry, indicating potential for support in regulatory consulting, compliance solutions, and market access services.

Market Opportunities With a revenue range of 25 to 50 million and ongoing product commercialization efforts, Agios presents opportunities for sales of clinical trial support, manufacturing partnerships, and healthcare analytics tailored to emerging biopharmaceutical innovators.

Agios Pharmaceuticals Tech Stack

Agios Pharmaceuticals uses 8 technology products and services including Microsoft SQL Server, Microsoft Excel, Google Fonts API, and more. Explore Agios Pharmaceuticals's tech stack below.

  • Microsoft SQL Server
    Database
  • Microsoft Excel
    Editors
  • Google Fonts API
    Font Scripts
  • ARISg
    Governance, Risk And Compliance
  • Modernizr
    Javascript Libraries
  • American Express
    Payment Processing
  • .NET
    Programming Languages
  • Microsoft Project
    Project Management

Media & News

Agios Pharmaceuticals's Email Address Formats

Agios Pharmaceuticals uses at least 1 format(s):
Agios Pharmaceuticals Email FormatsExamplePercentage
First.Last@agios.comJohn.Doe@agios.com
94%
F.Last@agios.comJ.Doe@agios.com
3%
LastF@agios.comDoeJ@agios.com
2%
Last@agios.comDoe@agios.com
1%

Frequently Asked Questions

What is Agios Pharmaceuticals's phone number?

Minus sign iconPlus sign icon
You can contact Agios Pharmaceuticals's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Agios Pharmaceuticals's stock symbol?

Minus sign iconPlus sign icon
Agios Pharmaceuticals is a publicly traded company; the company's stock symbol is AGIO.

What is Agios Pharmaceuticals's official website and social media links?

Minus sign iconPlus sign icon
Agios Pharmaceuticals's official website is agios.com and has social profiles on LinkedInCrunchbase.

What is Agios Pharmaceuticals's SIC code NAICS code?

Minus sign iconPlus sign icon
Agios Pharmaceuticals's SIC code is 2835 - In Vitro and In Vivo Diagnostic Substances NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Agios Pharmaceuticals have currently?

Minus sign iconPlus sign icon
As of July 2026, Agios Pharmaceuticals has approximately 645 employees across 5 continents, including North AmericaAsiaEurope. Key team members include Chief Commercial Officer: S. H.Vice President Regulatory Affairs: L. C.President: J. G.. Explore Agios Pharmaceuticals's employee directory with LeadIQ.

What industry does Agios Pharmaceuticals belong to?

Minus sign iconPlus sign icon
Agios Pharmaceuticals operates in the Pharmaceutical Manufacturing industry.

What technology does Agios Pharmaceuticals use?

Minus sign iconPlus sign icon
Agios Pharmaceuticals's tech stack includes Microsoft SQL ServerMicrosoft ExcelGoogle Fonts APIARISgModernizrAmerican Express.NETMicrosoft Project.

What is Agios Pharmaceuticals's email format?

Minus sign iconPlus sign icon
Agios Pharmaceuticals's email format typically follows the pattern of First.Last@agios.com. Find more Agios Pharmaceuticals email formats with LeadIQ.

How much funding has Agios Pharmaceuticals raised to date?

Minus sign iconPlus sign icon
As of July 2026, Agios Pharmaceuticals has raised $776M in funding. The last funding round occurred on Nov 07, 2019 for $256M.

When was Agios Pharmaceuticals founded?

Minus sign iconPlus sign icon
Agios Pharmaceuticals was founded in 2008.
Agios Pharmaceuticals logo

Agios Pharmaceuticals

Pharmaceutical ManufacturingMassachusetts, United States501-1000 Employees

Agios Pharmaceuticals is a commercial-stage biopharmaceutical company in the pharmaceutical manufacturing industry, located at 88 Sidney Street, Cambridge, Massachusetts. The company focuses on rare diseases, particularly hematology, and collaborates with patient communities to develop and deliver medicines aligned with their priorities. It aims to advance a growing pipeline by combining deep biological expertise with real-world insights, supported by an inclusive, collaborative culture. Agios has pursued licensing and collaboration arrangements, including exclusive global rights to cevidoplenib, a novel oral spleen tyrosine kinase inhibitor, and a partnership with Oscotec, as well as a distribution agreement for PYRUKYND across the European Economic Area, the United Kingdom, and Switzerland. The company engages with regulatory processes and agencies as part of its development programs, including collaboration with the U.S. FDA on labeling and REMS materials.

Section iconCompany Overview

Phone number
Website
agios.com
SIC Code
2835 - In Vitro and In Vivo Diagnostic Substances
Stock Symbol
AGIO
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Founded
2008
Employees
501-1000

Section iconFunding & Financials

  • $776M

    Agios Pharmaceuticals has raised a total of $776M of funding over 7 rounds. Their latest funding round was raised on Nov 07, 2019 in the amount of $256Mas a post_ipo_equity.

  • $25M$50M

    Agios Pharmaceuticals's revenue is estimated to be in the range of $25M$50M

Section iconFunding & Financials

  • $776M

    Agios Pharmaceuticals has raised a total of $776M of funding over 7 rounds. Their latest funding round was raised on Nov 07, 2019 in the amount of $256Mas a post_ipo_equity.

  • $25M$50M

    Agios Pharmaceuticals's revenue is estimated to be in the range of $25M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.